| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autism Spectrum Disorder | 23 | 2023 | 76 | 5.570 |
Why?
|
| Autistic Disorder | 47 | 2023 | 147 | 3.490 |
Why?
|
| Crime Victims | 7 | 2020 | 34 | 2.820 |
Why?
|
| Bullying | 5 | 2020 | 8 | 2.590 |
Why?
|
| Child Development Disorders, Pervasive | 13 | 2016 | 39 | 2.160 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 13 | 2021 | 183 | 1.760 |
Why?
|
| Child | 105 | 2023 | 6926 | 1.620 |
Why?
|
| Students | 5 | 2020 | 147 | 1.590 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2016 | 216 | 1.580 |
Why?
|
| Mental Disorders | 10 | 2020 | 371 | 1.580 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2021 | 153 | 1.360 |
Why?
|
| Aggression | 10 | 2017 | 320 | 1.250 |
Why?
|
| Adolescent | 75 | 2023 | 8979 | 1.160 |
Why?
|
| Smoking | 10 | 2021 | 609 | 1.090 |
Why?
|
| Cross-Cultural Comparison | 3 | 2020 | 34 | 1.060 |
Why?
|
| Serotonin | 15 | 2010 | 218 | 1.030 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 7 | 2009 | 46 | 1.020 |
Why?
|
| Child Behavior Disorders | 9 | 2008 | 76 | 0.860 |
Why?
|
| Obsessive-Compulsive Disorder | 14 | 2016 | 157 | 0.860 |
Why?
|
| Humans | 175 | 2023 | 86601 | 0.830 |
Why?
|
| Mental Health Services | 4 | 2022 | 48 | 0.830 |
Why?
|
| Violence | 4 | 2008 | 143 | 0.770 |
Why?
|
| Female | 113 | 2023 | 44507 | 0.760 |
Why?
|
| Child, Preschool | 47 | 2020 | 3611 | 0.760 |
Why?
|
| Male | 111 | 2021 | 40956 | 0.740 |
Why?
|
| Suicide | 4 | 2017 | 139 | 0.710 |
Why?
|
| Schools | 2 | 2018 | 71 | 0.690 |
Why?
|
| Republic of Korea | 10 | 2021 | 31 | 0.690 |
Why?
|
| Tourette Syndrome | 5 | 2021 | 25 | 0.680 |
Why?
|
| Defense Mechanisms | 1 | 2017 | 7 | 0.610 |
Why?
|
| Social Behavior Disorders | 4 | 2012 | 19 | 0.600 |
Why?
|
| Psychiatric Status Rating Scales | 14 | 2016 | 487 | 0.570 |
Why?
|
| Interpersonal Relations | 4 | 2020 | 170 | 0.560 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 69 | 0.550 |
Why?
|
| Social Behavior | 9 | 2020 | 294 | 0.530 |
Why?
|
| Morbidity | 1 | 2015 | 148 | 0.520 |
Why?
|
| Gene-Environment Interaction | 2 | 2021 | 103 | 0.520 |
Why?
|
| Adolescent Health Services | 2 | 2020 | 11 | 0.520 |
Why?
|
| Conduct Disorder | 2 | 2007 | 62 | 0.500 |
Why?
|
| Risk Factors | 21 | 2021 | 5416 | 0.490 |
Why?
|
| Pregnancy | 12 | 2021 | 2893 | 0.460 |
Why?
|
| Parenting | 3 | 2012 | 67 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2012 | 2270 | 0.450 |
Why?
|
| Blood Platelets | 6 | 2010 | 149 | 0.450 |
Why?
|
| Adolescent Behavior | 4 | 2012 | 106 | 0.430 |
Why?
|
| Surveys and Questionnaires | 11 | 2017 | 2501 | 0.430 |
Why?
|
| Linkage Disequilibrium | 15 | 2017 | 473 | 0.430 |
Why?
|
| Nerve Tissue Proteins | 6 | 2012 | 503 | 0.420 |
Why?
|
| Adult | 58 | 2021 | 25640 | 0.420 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 1621 | 0.410 |
Why?
|
| Receptors, Serotonin | 6 | 2002 | 34 | 0.410 |
Why?
|
| Psychotherapy | 2 | 2012 | 74 | 0.410 |
Why?
|
| Attention | 3 | 2021 | 388 | 0.410 |
Why?
|
| Bipolar Disorder | 4 | 2020 | 377 | 0.400 |
Why?
|
| Health Behavior | 3 | 2017 | 183 | 0.400 |
Why?
|
| Connectome | 3 | 2017 | 74 | 0.390 |
Why?
|
| Membrane Transport Proteins | 5 | 2002 | 166 | 0.390 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1169 | 0.380 |
Why?
|
| Psychometrics | 8 | 2020 | 327 | 0.380 |
Why?
|
| Smoking Cessation | 2 | 2003 | 230 | 0.380 |
Why?
|
| Research Design | 2 | 2012 | 594 | 0.370 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2020 | 103 | 0.360 |
Why?
|
| Demography | 2 | 2009 | 177 | 0.350 |
Why?
|
| Eye Movements | 2 | 2021 | 119 | 0.350 |
Why?
|
| Facial Expression | 2 | 2020 | 51 | 0.350 |
Why?
|
| Family Therapy | 2 | 2007 | 16 | 0.350 |
Why?
|
| Genotype | 20 | 2021 | 1850 | 0.340 |
Why?
|
| Schizophrenia | 2 | 2020 | 464 | 0.330 |
Why?
|
| Polymorphism, Genetic | 10 | 2007 | 819 | 0.330 |
Why?
|
| Family | 6 | 2021 | 311 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2017 | 2356 | 0.330 |
Why?
|
| Carrier Proteins | 5 | 2002 | 673 | 0.330 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 8 | 2010 | 45 | 0.330 |
Why?
|
| Registries | 1 | 2012 | 702 | 0.320 |
Why?
|
| Fluoxetine | 4 | 2009 | 42 | 0.320 |
Why?
|
| Brain | 6 | 2016 | 2216 | 0.320 |
Why?
|
| Membrane Glycoproteins | 4 | 2002 | 428 | 0.310 |
Why?
|
| International Cooperation | 1 | 2008 | 127 | 0.310 |
Why?
|
| Child Health Services | 1 | 2008 | 49 | 0.310 |
Why?
|
| Young Adult | 14 | 2022 | 5974 | 0.310 |
Why?
|
| Personality Assessment | 6 | 2010 | 98 | 0.310 |
Why?
|
| Korea | 8 | 2014 | 17 | 0.300 |
Why?
|
| Genome-Wide Association Study | 8 | 2021 | 1620 | 0.290 |
Why?
|
| Fenfluramine | 3 | 1993 | 20 | 0.290 |
Why?
|
| Phenotype | 9 | 2018 | 2377 | 0.290 |
Why?
|
| Bulimia Nervosa | 1 | 2007 | 108 | 0.290 |
Why?
|
| Antisocial Personality Disorder | 2 | 2009 | 91 | 0.290 |
Why?
|
| Parents | 8 | 2018 | 272 | 0.280 |
Why?
|
| Reproducibility of Results | 12 | 2020 | 2705 | 0.280 |
Why?
|
| Pregnant Women | 2 | 2003 | 35 | 0.280 |
Why?
|
| Comorbidity | 6 | 2020 | 943 | 0.280 |
Why?
|
| Causality | 3 | 2021 | 81 | 0.270 |
Why?
|
| Genetic Linkage | 5 | 2007 | 623 | 0.260 |
Why?
|
| Family Health | 6 | 2017 | 162 | 0.260 |
Why?
|
| Mental Health | 4 | 2023 | 162 | 0.260 |
Why?
|
| Diagnosis, Differential | 9 | 2016 | 1565 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2021 | 4210 | 0.250 |
Why?
|
| Tic Disorders | 4 | 2017 | 8 | 0.250 |
Why?
|
| Residential Treatment | 1 | 2004 | 5 | 0.250 |
Why?
|
| Pregnancy Complications | 3 | 2016 | 336 | 0.250 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 158 | 0.240 |
Why?
|
| Depressive Disorder | 4 | 2006 | 218 | 0.240 |
Why?
|
| Mood Disorders | 1 | 2004 | 81 | 0.240 |
Why?
|
| Intellectual Disability | 4 | 1998 | 186 | 0.240 |
Why?
|
| Social Class | 4 | 2012 | 127 | 0.230 |
Why?
|
| Prevalence | 3 | 2020 | 1239 | 0.220 |
Why?
|
| Maternal Behavior | 1 | 2003 | 54 | 0.220 |
Why?
|
| Air Pollution | 1 | 2023 | 68 | 0.210 |
Why?
|
| Juvenile Delinquency | 1 | 2002 | 27 | 0.210 |
Why?
|
| Maternal Exposure | 1 | 2002 | 57 | 0.210 |
Why?
|
| Anxiety Disorders | 2 | 2006 | 148 | 0.210 |
Why?
|
| Child Development | 2 | 2017 | 163 | 0.210 |
Why?
|
| Tics | 1 | 2021 | 4 | 0.210 |
Why?
|
| Age Factors | 10 | 2020 | 1849 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 3636 | 0.200 |
Why?
|
| Age of Onset | 8 | 2008 | 310 | 0.200 |
Why?
|
| Child Behavior | 3 | 2017 | 48 | 0.200 |
Why?
|
| Risk-Taking | 2 | 2017 | 148 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2023 | 296 | 0.190 |
Why?
|
| Brain Mapping | 2 | 2016 | 548 | 0.190 |
Why?
|
| Child Health | 2 | 2023 | 11 | 0.190 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 1801 | 0.190 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 174 | 0.190 |
Why?
|
| Global Health | 2 | 2015 | 193 | 0.190 |
Why?
|
| Crime | 1 | 2000 | 36 | 0.190 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 5 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2009 | 35 | 0.190 |
Why?
|
| Depression | 3 | 2017 | 473 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 1019 | 0.180 |
Why?
|
| Motion Perception | 1 | 2021 | 105 | 0.180 |
Why?
|
| Antipsychotic Agents | 3 | 2012 | 123 | 0.180 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2020 | 36 | 0.180 |
Why?
|
| Chromosome Aberrations | 5 | 2007 | 387 | 0.180 |
Why?
|
| Behavior | 1 | 2020 | 85 | 0.180 |
Why?
|
| Social Perception | 2 | 2016 | 95 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3352 | 0.170 |
Why?
|
| Adolescent Psychiatry | 1 | 2018 | 6 | 0.170 |
Why?
|
| Child Psychiatry | 1 | 2018 | 9 | 0.170 |
Why?
|
| Middle Aged | 25 | 2021 | 25017 | 0.170 |
Why?
|
| Caregivers | 1 | 2020 | 151 | 0.170 |
Why?
|
| Emotions | 2 | 2020 | 341 | 0.170 |
Why?
|
| Peer Group | 2 | 2017 | 72 | 0.160 |
Why?
|
| Time Factors | 6 | 2018 | 5209 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2022 | 319 | 0.160 |
Why?
|
| Brain Diseases | 2 | 2018 | 180 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 1999 | 63 | 0.160 |
Why?
|
| Haplotypes | 6 | 2011 | 642 | 0.160 |
Why?
|
| Stereotyped Behavior | 3 | 2014 | 11 | 0.160 |
Why?
|
| Self Report | 2 | 2017 | 288 | 0.160 |
Why?
|
| Citalopram | 2 | 2010 | 20 | 0.160 |
Why?
|
| Photic Stimulation | 4 | 2021 | 493 | 0.160 |
Why?
|
| Social Environment | 4 | 2008 | 188 | 0.160 |
Why?
|
| Excitatory Amino Acid Transporter 3 | 2 | 2008 | 5 | 0.150 |
Why?
|
| Behavior Rating Scale | 1 | 2017 | 6 | 0.150 |
Why?
|
| Dental Anxiety | 1 | 2017 | 2 | 0.150 |
Why?
|
| Leukemia, Lymphoid | 5 | 1983 | 72 | 0.150 |
Why?
|
| Self Concept | 1 | 2017 | 133 | 0.150 |
Why?
|
| Neurofeedback | 1 | 2016 | 4 | 0.150 |
Why?
|
| Social Communication Disorder | 1 | 2016 | 1 | 0.150 |
Why?
|
| Chromosome Mapping | 7 | 2007 | 1074 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1990 | 0.140 |
Why?
|
| Receptors, Glucocorticoid | 2 | 1993 | 120 | 0.140 |
Why?
|
| Norepinephrine | 3 | 1993 | 167 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2017 | 812 | 0.140 |
Why?
|
| Psychology, Adolescent | 2 | 2007 | 29 | 0.140 |
Why?
|
| Facial Recognition | 1 | 2016 | 15 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 111 | 0.140 |
Why?
|
| Propranolol | 1 | 2016 | 45 | 0.140 |
Why?
|
| Workplace | 1 | 2015 | 27 | 0.140 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 129 | 0.130 |
Why?
|
| Internet | 2 | 2017 | 312 | 0.130 |
Why?
|
| Parent-Child Relations | 2 | 2016 | 77 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2013 | 96 | 0.130 |
Why?
|
| Tryptophan | 2 | 2014 | 90 | 0.130 |
Why?
|
| DNA Copy Number Variations | 3 | 2011 | 171 | 0.130 |
Why?
|
| Auditory Perception | 1 | 2016 | 96 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 152 | 0.130 |
Why?
|
| Twin Studies as Topic | 1 | 2014 | 19 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 1994 | 375 | 0.130 |
Why?
|
| Communication Disorders | 2 | 2007 | 7 | 0.130 |
Why?
|
| Pattern Recognition, Visual | 1 | 2016 | 151 | 0.130 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 53 | 0.130 |
Why?
|
| Mental Recall | 1 | 2016 | 159 | 0.120 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 184 | 0.120 |
Why?
|
| Histidine Decarboxylase | 1 | 2014 | 6 | 0.120 |
Why?
|
| Double-Blind Method | 8 | 2016 | 1823 | 0.120 |
Why?
|
| Genetic Testing | 5 | 2007 | 535 | 0.120 |
Why?
|
| Internal-External Control | 2 | 2012 | 44 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2007 | 47 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2016 | 308 | 0.120 |
Why?
|
| Patient Care Team | 1 | 1996 | 280 | 0.120 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 157 | 0.120 |
Why?
|
| Infant | 11 | 2020 | 3045 | 0.120 |
Why?
|
| Frontal Lobe | 1 | 1994 | 130 | 0.120 |
Why?
|
| Lymphocytes | 3 | 1993 | 464 | 0.120 |
Why?
|
| Amino Acid Transport System X-AG | 2 | 2011 | 6 | 0.120 |
Why?
|
| Amygdala | 1 | 2013 | 84 | 0.110 |
Why?
|
| Placebos | 3 | 2004 | 218 | 0.110 |
Why?
|
| Glucose | 2 | 1994 | 638 | 0.110 |
Why?
|
| Clonidine | 1 | 1992 | 37 | 0.110 |
Why?
|
| Learning | 1 | 2016 | 280 | 0.110 |
Why?
|
| Intelligence | 5 | 2011 | 71 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 1993 | 148 | 0.110 |
Why?
|
| Logistic Models | 4 | 2009 | 1185 | 0.110 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2002 | 7 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2013 | 175 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 567 | 0.110 |
Why?
|
| Gene Frequency | 7 | 2012 | 677 | 0.100 |
Why?
|
| Neuroimaging | 3 | 2017 | 113 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 1993 | 273 | 0.100 |
Why?
|
| Down Syndrome | 2 | 1994 | 53 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2013 | 312 | 0.100 |
Why?
|
| Task Performance and Analysis | 3 | 2021 | 86 | 0.100 |
Why?
|
| Attitude to Health | 3 | 2007 | 220 | 0.100 |
Why?
|
| Socialization | 3 | 2006 | 13 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2014 | 405 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 188 | 0.100 |
Why?
|
| Physicians | 1 | 2018 | 673 | 0.100 |
Why?
|
| Osteosarcoma | 2 | 1985 | 158 | 0.100 |
Why?
|
| Pedigree | 8 | 2007 | 966 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2007 | 181 | 0.090 |
Why?
|
| Fixation, Ocular | 2 | 2021 | 48 | 0.090 |
Why?
|
| Child Abuse | 2 | 1993 | 78 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 617 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2010 | 19 | 0.090 |
Why?
|
| Thalamus | 1 | 2011 | 132 | 0.090 |
Why?
|
| Risperidone | 2 | 2001 | 23 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 294 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2010 | 207 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2009 | 10 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 970 | 0.090 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 24 | 0.090 |
Why?
|
| Agonistic Behavior | 1 | 2009 | 6 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 1985 | 322 | 0.090 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 67 | 0.090 |
Why?
|
| Introns | 6 | 2010 | 289 | 0.090 |
Why?
|
| Base Sequence | 6 | 2002 | 2330 | 0.090 |
Why?
|
| Impulsive Behavior | 1 | 1992 | 281 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2009 | 173 | 0.080 |
Why?
|
| Sex Factors | 6 | 2016 | 1054 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2003 | 678 | 0.080 |
Why?
|
| Psychological Tests | 2 | 2016 | 91 | 0.080 |
Why?
|
| Forecasting | 1 | 2009 | 304 | 0.080 |
Why?
|
| Mutation | 3 | 2014 | 3967 | 0.080 |
Why?
|
| Schools, Nursery | 1 | 2007 | 1 | 0.080 |
Why?
|
| Child Day Care Centers | 1 | 2007 | 6 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 216 | 0.080 |
Why?
|
| United States | 5 | 2023 | 6665 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 2001 | 3030 | 0.080 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 502 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1804 | 0.080 |
Why?
|
| Receptors, Oxytocin | 1 | 2007 | 10 | 0.080 |
Why?
|
| Irritable Mood | 2 | 2010 | 10 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2016 | 912 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 6 | 2002 | 927 | 0.070 |
Why?
|
| Memantine | 1 | 2006 | 10 | 0.070 |
Why?
|
| Public Health | 1 | 2008 | 129 | 0.070 |
Why?
|
| Information Services | 1 | 2006 | 23 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 78 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2023 | 2767 | 0.070 |
Why?
|
| Health Promotion | 1 | 2008 | 160 | 0.070 |
Why?
|
| Memory Disorders | 1 | 2006 | 69 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 674 | 0.070 |
Why?
|
| Models, Psychological | 2 | 2006 | 157 | 0.070 |
Why?
|
| Cognition | 3 | 2016 | 570 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 596 | 0.070 |
Why?
|
| Energy Intake | 1 | 1986 | 98 | 0.070 |
Why?
|
| Self-Injurious Behavior | 1 | 2008 | 105 | 0.070 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2005 | 11 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1196 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 1997 | 394 | 0.070 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 1985 | 32 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 740 | 0.070 |
Why?
|
| Stereotypic Movement Disorder | 1 | 2005 | 5 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 9 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2010 | 7988 | 0.070 |
Why?
|
| Psychology, Child | 1 | 2005 | 12 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 752 | 0.060 |
Why?
|
| Theophylline | 2 | 1996 | 34 | 0.060 |
Why?
|
| Sequence Deletion | 3 | 2000 | 205 | 0.060 |
Why?
|
| Affect | 1 | 2007 | 386 | 0.060 |
Why?
|
| Minisatellite Repeats | 3 | 2005 | 24 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2378 | 0.060 |
Why?
|
| Genome, Human | 3 | 2010 | 756 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 236 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1961 | 0.060 |
Why?
|
| Family Relations | 1 | 2004 | 35 | 0.060 |
Why?
|
| Translations | 1 | 2004 | 5 | 0.060 |
Why?
|
| Triiodothyronine | 1 | 1986 | 339 | 0.060 |
Why?
|
| Leukemia | 3 | 1982 | 320 | 0.060 |
Why?
|
| Brain Chemistry | 3 | 2007 | 121 | 0.060 |
Why?
|
| Prognosis | 8 | 1996 | 3674 | 0.060 |
Why?
|
| Psychopharmacology | 1 | 2004 | 26 | 0.060 |
Why?
|
| DNA Mutational Analysis | 5 | 2007 | 526 | 0.060 |
Why?
|
| Platelet Count | 3 | 2007 | 92 | 0.060 |
Why?
|
| Social Problems | 1 | 2003 | 10 | 0.060 |
Why?
|
| Maternal Welfare | 1 | 2003 | 9 | 0.060 |
Why?
|
| Arousal | 2 | 2016 | 170 | 0.060 |
Why?
|
| Alleles | 4 | 2012 | 1127 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 29 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2016 | 369 | 0.060 |
Why?
|
| Communication | 2 | 2017 | 440 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 309 | 0.060 |
Why?
|
| Anxiety | 1 | 2005 | 287 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 229 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2016 | 684 | 0.050 |
Why?
|
| Employment | 1 | 2002 | 52 | 0.050 |
Why?
|
| Sadism | 1 | 1982 | 3 | 0.050 |
Why?
|
| Receptors, Vasopressin | 1 | 2002 | 7 | 0.050 |
Why?
|
| Privacy | 1 | 2022 | 20 | 0.050 |
Why?
|
| Point Mutation | 2 | 2000 | 246 | 0.050 |
Why?
|
| Amphetamines | 1 | 2002 | 18 | 0.050 |
Why?
|
| Secretin | 1 | 2001 | 6 | 0.050 |
Why?
|
| Alternative Splicing | 2 | 2000 | 201 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 1576 | 0.050 |
Why?
|
| Decision Making | 1 | 2007 | 642 | 0.050 |
Why?
|
| Amitriptyline | 1 | 1981 | 11 | 0.050 |
Why?
|
| Nortriptyline | 1 | 1981 | 6 | 0.050 |
Why?
|
| Amantadine | 1 | 2001 | 18 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2018 | 1351 | 0.050 |
Why?
|
| Prisoners | 1 | 1982 | 40 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2021 | 47 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 26 | 0.050 |
Why?
|
| Dopamine Agents | 1 | 2001 | 29 | 0.050 |
Why?
|
| Priapism | 1 | 2001 | 5 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 127 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2002 | 153 | 0.050 |
Why?
|
| Infusions, Intravenous | 4 | 2001 | 429 | 0.050 |
Why?
|
| Lithium | 1 | 2001 | 59 | 0.050 |
Why?
|
| Norway | 1 | 2020 | 8 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2000 | 19 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 141 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 999 | 0.050 |
Why?
|
| Aneuploidy | 2 | 1997 | 55 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2022 | 290 | 0.050 |
Why?
|
| Genetic Markers | 4 | 2007 | 476 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 1999 | 27 | 0.050 |
Why?
|
| Chicago | 2 | 2003 | 1379 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 159 | 0.050 |
Why?
|
| Pseudogenes | 1 | 1999 | 35 | 0.040 |
Why?
|
| Microsatellite Repeats | 4 | 2002 | 144 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1999 | 65 | 0.040 |
Why?
|
| Japan | 1 | 2020 | 307 | 0.040 |
Why?
|
| Nuclear Family | 2 | 2011 | 92 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 399 | 0.040 |
Why?
|
| Interview, Psychological | 1 | 1999 | 69 | 0.040 |
Why?
|
| Language Development | 2 | 2012 | 23 | 0.040 |
Why?
|
| Biometric Identification | 1 | 2019 | 1 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1673 | 0.040 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1979 | 19 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1980 | 286 | 0.040 |
Why?
|
| Reaction Time | 1 | 2020 | 309 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 219 | 0.040 |
Why?
|
| Ligases | 1 | 1999 | 45 | 0.040 |
Why?
|
| Exons | 4 | 2002 | 450 | 0.040 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2018 | 18 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 1981 | 266 | 0.040 |
Why?
|
| Aged | 7 | 2017 | 18402 | 0.040 |
Why?
|
| Megaloblasts | 1 | 1977 | 1 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 202 | 0.040 |
Why?
|
| Personality Inventory | 1 | 1998 | 108 | 0.040 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1977 | 12 | 0.040 |
Why?
|
| DNA Primers | 3 | 2007 | 543 | 0.040 |
Why?
|
| Indians, North American | 1 | 1977 | 48 | 0.040 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2017 | 10 | 0.040 |
Why?
|
| Maternal Age | 1 | 1997 | 44 | 0.040 |
Why?
|
| Nonverbal Communication | 2 | 2007 | 5 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2018 | 124 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 1977 | 42 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 482 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 110 | 0.040 |
Why?
|
| Electroencephalography | 2 | 2017 | 707 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 52 | 0.040 |
Why?
|
| Personality Development | 1 | 1996 | 23 | 0.040 |
Why?
|
| Seasons | 1 | 1998 | 223 | 0.040 |
Why?
|
| Landau-Kleffner Syndrome | 1 | 1996 | 2 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 2017 | 128 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 159 | 0.040 |
Why?
|
| Bone and Bones | 1 | 1977 | 265 | 0.040 |
Why?
|
| Radioligand Assay | 2 | 1993 | 32 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 1996 | 48 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 120 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 176 | 0.030 |
Why?
|
| Graft Survival | 1 | 1980 | 884 | 0.030 |
Why?
|
| Individuality | 1 | 2016 | 109 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 2 | 1994 | 103 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2016 | 103 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 3 | 2006 | 937 | 0.030 |
Why?
|
| Nicotine | 1 | 1997 | 194 | 0.030 |
Why?
|
| Pharmacogenetics | 2 | 2010 | 434 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2017 | 319 | 0.030 |
Why?
|
| Caffeine | 1 | 1996 | 81 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2007 | 14 | 0.030 |
Why?
|
| Lod Score | 2 | 2007 | 152 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 572 | 0.030 |
Why?
|
| Immune Sera | 1 | 1974 | 52 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1996 | 263 | 0.030 |
Why?
|
| Binding Sites | 2 | 1993 | 1098 | 0.030 |
Why?
|
| Raclopride | 1 | 2014 | 3 | 0.030 |
Why?
|
| Psychopathology | 1 | 2014 | 29 | 0.030 |
Why?
|
| Oxazines | 1 | 2014 | 13 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 28 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6501 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 27 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2016 | 8475 | 0.030 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 35 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 44 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 220 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 492 | 0.030 |
Why?
|
| Observation | 2 | 2005 | 37 | 0.030 |
Why?
|
| Lysergic Acid | 1 | 1993 | 1 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1993 | 15 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1993 | 12 | 0.030 |
Why?
|
| Leukocytes | 1 | 1974 | 202 | 0.030 |
Why?
|
| Alprostadil | 1 | 1993 | 25 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1994 | 142 | 0.030 |
Why?
|
| Colforsin | 1 | 1993 | 74 | 0.030 |
Why?
|
| Plasma | 1 | 1993 | 50 | 0.030 |
Why?
|
| Paroxetine | 1 | 1993 | 26 | 0.030 |
Why?
|
| Amphetamine | 1 | 2014 | 101 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1992 | 45 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 864 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.030 |
Why?
|
| Hypotension | 1 | 1992 | 70 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 1546 | 0.030 |
Why?
|
| Biological Transport | 1 | 1993 | 396 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1994 | 2436 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1830 | 0.030 |
Why?
|
| Anisotropy | 1 | 2011 | 62 | 0.030 |
Why?
|
| Education, Special | 1 | 2011 | 10 | 0.030 |
Why?
|
| Homozygote | 1 | 2011 | 200 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1974 | 728 | 0.020 |
Why?
|
| Karyotyping | 2 | 1985 | 250 | 0.020 |
Why?
|
| Teaching | 1 | 1992 | 147 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 1991 | 28 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 989 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2011 | 67 | 0.020 |
Why?
|
| Sheltered Workshops | 1 | 1990 | 1 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 1974 | 763 | 0.020 |
Why?
|
| Hospital Departments | 1 | 1990 | 12 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2062 | 0.020 |
Why?
|
| Social Adjustment | 1 | 1990 | 46 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2016 | 1143 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2010 | 47 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 239 | 0.020 |
Why?
|
| Efficiency | 1 | 1990 | 40 | 0.020 |
Why?
|
| Gene Expression | 1 | 1994 | 1284 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1994 | 724 | 0.020 |
Why?
|
| Survival Rate | 1 | 1993 | 1860 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1924 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 260 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2009 | 15 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1982 | 220 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 894 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2009 | 48 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 155 | 0.020 |
Why?
|
| DNA | 2 | 2007 | 1294 | 0.020 |
Why?
|
| Interviews as Topic | 2 | 2002 | 319 | 0.020 |
Why?
|
| Mercaptopurine | 3 | 1994 | 53 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1994 | 1981 | 0.020 |
Why?
|
| Methotrexate | 3 | 1994 | 249 | 0.020 |
Why?
|
| Community Participation | 1 | 2008 | 36 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2007 | 8 | 0.020 |
Why?
|
| Environment | 1 | 2009 | 219 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2007 | 27 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 26 | 0.020 |
Why?
|
| Asperger Syndrome | 1 | 2006 | 4 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2007 | 48 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2006 | 62 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 307 | 0.020 |
Why?
|
| Language Development Disorders | 1 | 2006 | 24 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 758 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 602 | 0.020 |
Why?
|
| Health Policy | 1 | 2008 | 180 | 0.020 |
Why?
|
| Oxytocin | 1 | 2007 | 71 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1977 | 74 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2006 | 152 | 0.020 |
Why?
|
| Mother-Child Relations | 1 | 1986 | 26 | 0.020 |
Why?
|
| Object Attachment | 1 | 1986 | 20 | 0.020 |
Why?
|
| Child Welfare | 1 | 1986 | 39 | 0.020 |
Why?
|
| Body Image | 1 | 1986 | 76 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1685 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1985 | 74 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2008 | 326 | 0.020 |
Why?
|
| Gestational Age | 1 | 2006 | 311 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1985 | 114 | 0.020 |
Why?
|
| Cues | 1 | 2006 | 175 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 879 | 0.020 |
Why?
|
| Neoplasms | 1 | 1980 | 2897 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1985 | 265 | 0.020 |
Why?
|
| Risk | 1 | 1986 | 674 | 0.020 |
Why?
|
| Empathy | 1 | 1986 | 147 | 0.010 |
Why?
|
| Kinetics | 2 | 1994 | 1513 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1983 | 101 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 1986 | 231 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 162 | 0.010 |
Why?
|
| Penetrance | 1 | 2002 | 44 | 0.010 |
Why?
|
| California | 1 | 2002 | 138 | 0.010 |
Why?
|
| Cytarabine | 2 | 1974 | 218 | 0.010 |
Why?
|
| Criminal Psychology | 1 | 1982 | 2 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 2002 | 21 | 0.010 |
Why?
|
| Codon, Initiator | 1 | 2002 | 21 | 0.010 |
Why?
|
| Hematocrit | 1 | 1982 | 68 | 0.010 |
Why?
|
| Urography | 1 | 1982 | 45 | 0.010 |
Why?
|
| Lymphoma | 2 | 1983 | 262 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1982 | 244 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1982 | 123 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 303 | 0.010 |
Why?
|
| DNA Replication | 1 | 2002 | 164 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2002 | 197 | 0.010 |
Why?
|
| Chromogranins | 1 | 2000 | 11 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1990 | 1004 | 0.010 |
Why?
|
| Macaca | 1 | 2000 | 87 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2000 | 2 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2000 | 49 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2000 | 85 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 1 | 1980 | 40 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 11352 | 0.010 |
Why?
|
| Electrophoresis, Capillary | 1 | 1999 | 12 | 0.010 |
Why?
|
| Wechsler Scales | 2 | 1990 | 21 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1999 | 147 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3241 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 916 | 0.010 |
Why?
|
| Adjustment Disorders | 1 | 1979 | 6 | 0.010 |
Why?
|
| Heterozygote | 1 | 2000 | 365 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 1999 | 13 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2001 | 195 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1999 | 31 | 0.010 |
Why?
|
| Animals | 2 | 2014 | 26581 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1979 | 19 | 0.010 |
Why?
|
| Automation | 1 | 1999 | 106 | 0.010 |
Why?
|
| Recurrence | 1 | 1982 | 1139 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2000 | 339 | 0.010 |
Why?
|
| Prader-Willi Syndrome | 1 | 1998 | 8 | 0.010 |
Why?
|
| Angelman Syndrome | 1 | 1998 | 7 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1980 | 330 | 0.010 |
Why?
|
| Wisconsin | 1 | 1977 | 39 | 0.010 |
Why?
|
| Consanguinity | 1 | 1977 | 73 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 242 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 268 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1999 | 165 | 0.010 |
Why?
|
| Multigene Family | 1 | 1998 | 202 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1977 | 114 | 0.010 |
Why?
|
| Syndrome | 1 | 1977 | 446 | 0.010 |
Why?
|
| Immunity | 1 | 1977 | 136 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1983 | 1376 | 0.010 |
Why?
|
| Contrast Media | 1 | 1982 | 1077 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1977 | 281 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1977 | 265 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1977 | 255 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 853 | 0.010 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 1976 | 14 | 0.010 |
Why?
|
| Azure Stains | 1 | 1976 | 6 | 0.010 |
Why?
|
| Carcinoma | 1 | 1980 | 436 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1977 | 293 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 348 | 0.010 |
Why?
|
| Puberty | 1 | 1976 | 59 | 0.010 |
Why?
|
| Maryland | 1 | 1976 | 35 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 53 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1980 | 374 | 0.010 |
Why?
|
| Trypsin | 1 | 1976 | 95 | 0.010 |
Why?
|
| Mothers | 1 | 1997 | 141 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 65 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1977 | 326 | 0.010 |
Why?
|
| Kidney | 1 | 1982 | 1241 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1983 | 1195 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1994 | 37 | 0.010 |
Why?
|
| Reproduction | 1 | 1976 | 195 | 0.010 |
Why?
|
| Nitrosourea Compounds | 1 | 1974 | 9 | 0.010 |
Why?
|
| Thioguanine | 1 | 1974 | 17 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1976 | 249 | 0.010 |
Why?
|
| Prednisolone | 1 | 1974 | 41 | 0.010 |
Why?
|
| Asparaginase | 1 | 1974 | 35 | 0.010 |
Why?
|
| Vincristine | 1 | 1974 | 111 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 2232 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 777 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1994 | 138 | 0.010 |
Why?
|
| Biomarkers | 1 | 2000 | 1718 | 0.010 |
Why?
|
| Counseling | 1 | 1974 | 145 | 0.010 |
Why?
|
| DNA Methylation | 1 | 1997 | 628 | 0.010 |
Why?
|
| Spiperone | 1 | 1991 | 2 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1991 | 134 | 0.010 |
Why?
|
| Epilepsies, Partial | 1 | 1991 | 42 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1994 | 1538 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 1990 | 21 | 0.010 |
Why?
|
| Cost Control | 1 | 1990 | 44 | 0.010 |
Why?
|
| Child of Impaired Parents | 1 | 1990 | 19 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 1990 | 115 | 0.010 |
Why?
|
| Vocabulary | 1 | 1988 | 16 | 0.010 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 1990 | 93 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 1204 | 0.010 |
Why?
|
| Remission Induction | 1 | 1989 | 722 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1980 | 2261 | 0.000 |
Why?
|
| Seizures | 1 | 1989 | 295 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1976 | 2357 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1989 | 1313 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1983 | 316 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1983 | 372 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 2600 | 0.000 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1976 | 11 | 0.000 |
Why?
|
| Amenorrhea | 1 | 1976 | 27 | 0.000 |
Why?
|
| Menarche | 1 | 1976 | 24 | 0.000 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1976 | 147 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1976 | 81 | 0.000 |
Why?
|
| Ovary | 1 | 1976 | 257 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1971 | 238 | 0.000 |
Why?
|